factual
Melflufen approved on weak trial, may have harmed patients
Melflufen, a 1960s drug with a small molecule added, was approved based on an uncontrolled myeloma study, then in a randomized trial against the weakest acceptable control arm showed no survival benefit with a hazard ratio trending toward harm—illustrating that taxpayer money paid for a drug that may have hurt patients relative to not having it at all.
factualpending
Speaker
Vinay PrasadEvidence Quote
“the hazard ratio trends towards harm... the company was asked to withdraw the product from the U.S. market.”
Created: 6/13/2026, 3:32:57 AM
Your notes
Loading notes...